NCT06591650View on ClinicalTrials.gov

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

March 15, 2026

Study Completion Date

September 15, 2027

Conditions

Gallbladder Cancer Unresectable

Interventions

DRUG

gemcitabine hydrochloride

800 mg/m\^2, intravenous (IV) over 30 minutes, Days 1,8, every 21 days.

DRUG

Cisplatin

25 mg/m\^2, intravenous (IV) over 60 minutes, Days 1,8, every 21 days.

DRUG

Nab-paclitaxel

100 mg/m\^2, intravenous (IV) over 30 minutes, Days 1,8, every 21 days.

DRUG

Durvalumab

1500mg, intravenous (IV) over 30 minutes, Days 1, every 21 days.

Trial Locations (1)

200040

Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT06591650 - Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer | Biotech Hunter | Biotech Hunter